1-2 of 2
Klaus Podar, MDPhD
Close
Sort by
Journal Articles

Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

Irene Manrique, PhD, Richard Greil, MD, Johannes Andel, MD, Siegfried Sormann, MD, Bernd L. Hartmann, MD, Klaus Podar, MDPhD, Alexander Egle, MD, Andreas Petzer, MD, Niklas Zojer, MD, Reinhard Ruckser, MD, Boris Bozic, MD, Clemens A. Schmitt, MD, Sigrid Machherndl-Spandl, MD, Hermine Agis, MD, Martin Schreder, MD, Maria-Theresa Krauth, MD, Christoph Tinchon, MD, Michael Fillitz, MD, Thomas Melchardt, MD PhD, Bruno Paiva, PhD, Heinz Ludwig, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 29–30.
https://doi.org/10.1182/blood-2020-140918
Published: 2020
Journal Articles

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Heinz Ludwig, MD, Thomas Melchardt, MD PhD, Johannes Andel, MD, Eberhard Gunsilius, MD, Siegfried Sormann, MD, Axel Hinke, PhD, Bernd L. Hartmann, MD, Klaus Podar, MDPhD, Wolfgang Willenbacher, MD PhD, Alexander Egle, MD, Andreas Petzer, MD, Niklas Zojer, MD, Ewald Wöll, MD, Reinhard Ruckser, MD, Boris Bozic, MD, Clemens A. Schmitt, MD, Sigrid Machherndl-Spandl, MD, Maria-Theresa Krauth, MD, Martin Schreder, MD, Hermine Agis, MD, Christoph Tinchon, MD, Michael Fillitz, MD, Richard Greil, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–29.
https://doi.org/10.1182/blood-2020-140701
Published: 2020